Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimotuzumab and concurrent intensity-modulated radiation therapy and chemotherapy study in patients with locally advanced cervical squamous cell cancer

Next Previous
Trial Profile

Nimotuzumab and concurrent intensity-modulated radiation therapy and chemotherapy study in patients with locally advanced cervical squamous cell cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Nimotuzumab (Primary) ; Ropidoxuridine (Primary)
  • Indications Cervical cancer; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 10 Jun 2019 New trial record
  • 04 Jun 2019 Results assessing safety and efficacy of Nimotuzumab plus concurrent IMRT and chemotherapy in patients with locally advanced cervical squamous cell cancer, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top